BioAge axes obesity asset over liver toxicity, pivots to preclinical prospects Atalanta loads crossbow with $97M, targeting neuro trial starts for 2 RNAi therapies Versant launches another obesity biotech with $65M series A and 'clinic-ready' GIP antibody 'No new studies are being launched': NIH explains the impact of Trump administration’s freeze Leap crashes as midphase data mark end of gastric cancer program Tris builds clinical case for opioid alternative by showing its pain drug is less likely to be abused UPDATED: Cell therapy biotech Aurion eyes IPO despite legal pushback from investor Longtime manufacturer ITM's lead radiotherapy outperforms standard of care in phase 3 neuroendocrine tumor trial Takeda regains home rights to phase 3-stage depression drug from Neurocrine | 